Market open
InspireMD/$NSPR
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About InspireMD
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
Ticker
$NSPR
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Tel Aviv, Israel
Employees
68
Website
InspireMD Metrics
BasicAdvanced
$61M
Market cap
-
P/E ratio
-$0.74
EPS
0.97
Beta
-
Dividend rate
Price and volume
Market cap
$61M
Beta
0.97
52-week high
$3.42
52-week low
$1.81
Average daily volume
23K
Financial strength
Current ratio
7.443
Quick ratio
7.024
Long term debt to equity
1.681
Total debt to equity
2.831
Management effectiveness
Return on assets (TTM)
-31.02%
Return on equity (TTM)
-54.55%
Valuation
Price to revenue (TTM)
12.499
Price to book
1.28
Price to tangible book (TTM)
1.28
Price to free cash flow (TTM)
-4.409
Growth
Revenue change (TTM)
22.86%
Earnings per share change (TTM)
-55.25%
3-year revenue growth (CAGR)
27.32%
3-year earnings per share growth (CAGR)
-35.29%
What the Analysts think about InspireMD
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for InspireMD stock.
InspireMD Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
InspireMD Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
InspireMD News
AllArticlesVideos
InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System
GlobeNewsWire·3 weeks ago
InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System
GlobeNewsWire·1 month ago
InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for InspireMD stock?
InspireMD (NSPR) has a market cap of $61M as of November 08, 2024.
What is the P/E ratio for InspireMD stock?
The price to earnings (P/E) ratio for InspireMD (NSPR) stock is 0 as of November 08, 2024.
Does InspireMD stock pay dividends?
No, InspireMD (NSPR) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next InspireMD dividend payment date?
InspireMD (NSPR) stock does not pay dividends to its shareholders.
What is the beta indicator for InspireMD?
InspireMD (NSPR) has a beta rating of 0.97. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.